PET and Cardiac Amyloidosis: Which Possible Role?

PET has recently demonstrated promising capabilities in the diagnosis and differentiation of various forms of CA. Tracers labeled with 18F, such as 18F-flutemetamol, 18F-florbetapir, and 18F-florbetaben, are being increasingly researched due to their extended half-life, eliminating the requirement for on-site cyclotrons. Unlike bone tracers, PET amyloid-binding tracers exhibit a higher affinity for light-chain fibrils, potentially enabling accurate differentiation between various types of CA. The methodology for measuring tracer uptake in PET imaging, whether dynamic or static, facilitates the quantification of disease severity and could act as a marker for monitoring the disease, assessing treatment response.